

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-742-F  
(400/132)

Serial No.

10/665,951



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

McSwiggen et al.

**Filing Date:**

September 18, 2003

**Group:**

**U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
AB	*	09/226,044	07/12/01	Hoffman et al.			
	*	10/151,116	05/17/02	Matulic-Adamic et al.			
	*	10/201,394	08/13/01	Vargeese et al.			
	*	10/287,949	11/04/02	Pavco			
	*	10/306,747	11/27/02	Pavco			
	*	10/427,160	04/30/03	Vargeese et al.			
	*	10/438,493	05/15/03	Pavco et al.			
	*	10/444,853	05/23/03	McSwiggen et al.			
	*	10/664,668	09/18/03	McSwiggen et al.			
	*	10/664,767	09/16/03	McSwiggen et al.			
	*	10/665,255	09/16/03	McSwiggen et al.			
	*	10/665,951	09/18/03	McSwiggen et al.			
	*	10/670,011	09/23/03	McSwiggen et al.			
	*	10/693,059	10/23/03	McSwiggen et al.			
	*	10/712,633	11/13/03	McSwiggen et al.			
	*	10/720,448	11/24/03	McSwiggen et al.			

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**FORM PTO-1449**  
(Rev. 2-32)

**U.S. Department of Commerce**  
**Patent and Trademark Office**

**Atty. Docket No.**

02-742-F  
(400/132)

**Serial No.**

10/665,951

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

McSwiggen et al.

**Filing Date:**

September 18, 2003

**Group:**

AB	*	10/727,780	12/03/03	Vaish et al.			
	*	10/757,803	01/14/04	McSwiggen et al.			
	*	10/758,155	01/12/04	McSwiggen et al.			
	*	10/764,957	01/26/04	McSwiggen et al.			
	*	10/831,620	04/23/04	McSwiggen et al.			
	*	2001/0007666	07/12/01	Hoffman et al.			
	*	2002/0130430	09/19/02	Castor			
	*	2004/0037780	02/06/04	Parsons et al.			
	*	60/082,404	04/20/98	Thömspon et al.			
	*	60/334,461	11/30/01	Pavco			
	*	60/358,580	02/20/02	Beigelman et al.			
	*	60/363,124	03/11/02	Beigelman et al.			
	*	60/386,782	06/06/02	Beigelman et al.			
	*	60/393,796	07/03/02	McSwiggen et al.			
	*	60/399,348	07/29/02	McSwiggen et al.			
	*	60/402,996	08/13/02	Usman et al.			
	*	60/406,784	08/29/02	Beigelman et al.			
	*	60/408,378	09/05/02	Beigelman et al.			
	*	60/409,293	09/09/02	Beigelman et al.			

**EXAMINER**

/Amy Bowman/

**DATE CONSIDERED**

06/08/2006

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-742-F  
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

AB	*	60/440,129	01/15/03	Beigelman et al.			
AB	*	60/543,480	02/10/04	Jadhav et al.			

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
AB	*	4,501,729	02/26/85	Boucher et al.			
	*	5,138,045	08/11/92	Cook et al.			
	*	5,214,136	05/25/93	Lin et al.			
	*	5,334,711	08/02/94	Sproat et al.			
	*	5,624,803	04/29/97	Noonberg et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,631,360	05/20/97	Usman et al.			
	*	5,670,633	09/23/97	Cook et al.			
	*	5,672,695	09/30/97	Eckstein et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,792,847	08/11/98	Buhr et al.			
	*	5,804,683	09/08/98	Usman et al.			
	*	5,814,620	09/29/98	Robinson et al.			

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>Atty. Docket No.</b>  02-742-F (400/132)	<b>Serial No.</b>  10/665,951
	<b>Applicant:</b>  McSwiggen et al.	
	<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>

AB	*	5,831,071	11/03/98	Usman et al.			
	*	5,854,038	12/29/98	Sullenger et al.			
	*	5,889,136	03/30/99	Scaringe et al.			
	*	5,898,031	04/27/99	Crooke			
	*	5,902,880	05/11/99	Thompson			
	*	5,998,203	12/07/99	Adamic et al.			
	*	6,001,311	12/14/99	Brennen			
	*	6,005,087	12/21/99	Cook et al.			
	*	6,008,400	12/28/99	Scaringe et al.			
	*	6,054,576	04/25/00	Bellon et al.			
	*	6,107,094	08/22/00	Crooke			
	*	6,111,086	08/29/00	Scaringe et al.			
	*	6,117,657	09/12/00	Usman et al.			
	*	6,146,886	11/14/00	Thompson et al.			
	*	6,153,737	11/28/00	Manoharan et al.			
	*	6,162,909	12/19/00	Bellon et al.			
	*	6,180,613	01/30/01	Kaplitt et al.			
	*	6,235,310	05/22/01	Wang et al.			
	*	6,248,878	06/19/01	Matulic-Adamic et al.			

<b>EXAMINER</b>  /Amy Bowman/	<b>DATE CONSIDERED</b>  06/08/2006
-------------------------------------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-742-F  
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

McSwiggen et al.

**Filing Date:**

September 18, 2003

**Group:**

AB	*	6,300,074	10/09/01	Gold et al.			
	*	6,303,773	10/16/01	Bellon et al.			
	*	6,335,434	01/01/02	Guzaev et al.			
	*	6,353,098	03/05/02	Usman et al.			
	*	6,362,323	03/26/01	Usman et al.			
	*	6,395,713	05/28/02	Beigelman et al.			
	*	6,437,117	08/20/02	Usman et al.			
	*	6,447,796	09/10/02	Vook et al.			
	*	6,469,158	10/22/02	Usman et al.			
	*	6,476,205	11/05/02	Buhr et al.			
	*	6,506,559	01/14/03	Fire et al.			
	*	6,528,631	03/04/03	Cook et al.			
	*	6,565,885	05/20/03	Tarara et al.			
	*	6,582,728	06/24/03	Platz et al.			
	*	6,586,524	07/01/03	Sagara			
✓	*	6,592,904	07/15/03	Platz et al.			

**FOREIGN PATENT DOCUMENTS**

							Translation
		Document	Date	Country	Class	Subclass	

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-742-F  
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

		Number						
							Yes	No
AB	1.	4037501	08/03/00	AU (Kreutzer et al.)				
	2.	2,359,180	08/03/00	CA (Kreutzer et al.)				
	3.	1144623	08/03/00	EP (Kreutzer et al.)				
	4.	89/02439	03/23/89	WO (Arnold et al.)				
	5.	90/14090	11/29/90	WO (Gillespie et al.)				
	6.	91/03162	03/21/91	WO (Rossi et al.)				
	7.	92/07065	04/30/92	WO (Eckstein et al.)				
	8.	93/15187	08/05/93	WO (Usman et al.)				
	9.	93/23569	11/25/93	WO (Draper et al.)				
	10.	94/02595	02/03/94	WO (Sullivan et al.)				
	11.	94/01550	01/20/94	WO (Agrawal et al.)				
	12.	95/06731	03/09/95	WO (Usman et al.)				
	13.	95/11910	05/04/95	WO (Dudycz et al.)				
	14.	96/10390	04/11/96	WO (Ansell et al.)				
	15.	96/10391	04/11/96	WO (Choi et al.)				
	16.	96/10392	04/11/96	WO (Holland et al.)				
	17.	96/18736	06/20/96	WO (Beigelman et al.)				
	18.	97/26270	07/24/97	WO (Wincott et al.)				

EXAMINER

/Amy Bowman/

DATE CONSIDERED 06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

MCDONNELL BOEHNE  
HULBERT & BERGHOFF LLP  
300 SOUTH WACKER DRIVE  
CHICAGO, ILLINOIS 60606  
TELEPHONE (312) 913-0001

The PTO did not receive the following  
listed items(s) 4037501 (AU)

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-742-F  
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

McSwiggen et al.

**Filing Date:**

September 18, 2003

**Group:**

AB	19.	98/13526	04/02/98	WO (Woolf et al.)				
	20.	99/07409	02/18/99	WO (Deschamps de Paillette et al.)				
	21.	99/14226	03/25/99	WO (Wengel et al.)				
	22.	99/31262	06/24/99	WO (Barry et al.)				
	23.	99/32619	07/01/99	WO (Fire et al.)				
	24.	99/49029	09/30/99	WO (Graham et al.)				
	25.	99/53050	10/21/99	WO (Waterhouse et al.)				
	26.	99/54459	10/28/99	WO (Thompson et al.)				
	27.	99/61631	12/02/99	WO (Heifetz et al.)				
	28.	00/01846	01/13/00	WO (Plaetinck et al.)				
	29.	00/44895	08/03/00	WO (Kreutzer et al.)				
	30.	00/44914	08/03/00	WO (Li et al. )				
	31.	00/49035	08/24/00	WO (Sheen)				
	32.	00/53722	09/14/00	WO (O'Hare et al.)				
	33.	00/63364	10/26/00	WO (Pachuk et al.)				
	34.	00/66604	11/09/00	WO (Wengel et al.)				
	35.	01/04313	01/18/01	WO (Satishchandran et al.)				
	36.	01/29058	04/26/01	WO (Mello et al.)				
	37.	01/36646	05/25/01	WO (Zernicka-Goetz et al.)				

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 02-742-F (400/132)	<b>Serial No.</b> 10/665,951
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> September 18, 2003	<b>Group:</b>

AB	38.	01/38551	05/31/01	WO (Grossniklaus et al.)				
	39.	01/42443	06/14/01	WO (Churikov et al.)				
	40.	01/49844	07/12/01	WO (Driscoll et al.)				
	41.	01/53475	07/26/01	WO (Cogoni et al.)				
	42.	01/68836	09/20/01	WO (Beach et al.)				
	43.	01/70944	09/27/01	WO (Honer et al.)				
	44.	01/70949	09/27/01	WO (Graham et al.)				
	45.	01/72774	10/04/01	WO (Deak et al.)				
	46.	01/75164	10/11/01	WO (Tuschl et al.)				
	47.	01/92513	12/06/01	WO (Arndt et al.)				
	48.	01/96584	12/20/01	WO (Mushegian et al.)				
	49.	02/055692	07/18/02	WO (Kreutzer et al.)				
	50.	02/055693	07/18/02	WO (Kreutzer et al.)				
	51.	02/22636	03/21/02	WO (Bennett et al.)				
	52.	02/38805	05/15/02	WO (Echeverri et al.)				
	53.	02/44321	06/06/02	WO (Tuschl et al.)				
	54.	02/096927	12/05/02	WO (Pavco)				
	55.	03/24420	03/27/03	WO (Alheim et al.)				
V	56.	03/46185	06/05/03	WO (Wang et al.)				

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 02-742-F (400/132)	<b>Serial No.</b> 10/665,951
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> September 18, 2003	<b>Group:</b>

AB	57.	03/47518	06/12/03	WO (Wang et al.)				
	58.	PCT/US02/15876	05/20/02	Beigelman et al.				
	59.	PCT/US02/17674	05/29/02	WO (Pavco et al.)				
	60.	PCT/US03/05022	02/20/03	WO (McSwiggen et al.)				
	61.	PCT/US03/05028	02/20/03	McSwiggen et al.				
	62.	PCT/US03/05346	02/20/03	McSwiggen et al.				
	63.	WO 03/064625	02/03/03	WO (Woolf et al.)				
	64.	WO 03/064626	02/03/03	WO (Woolf et al.)				
	65.	WO 03/030989	04/17/03	WO (Behar et al.)				
	66.	WO 03/043689	05/03/03	WO (Behar et al.)				
	67.	WO 04/013280	05/26/03	WO (Davidson et al.)				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

AB	68.	Adah et al., "Chemistry and Biochemistry of 2',5'-Oligoadenylate-Based Antisense Strategy," <i>Current Medicinal Chemistry</i> , 8, 1189-1212 (2001)
	69.	Aiello et al., "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders," <i>The New England Journal of Medicine</i> 331(22):1480-1487 (1994)
	70.	Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," <i>Trends Cell Biol.</i> 2:139-144 (1992)
	71.	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <i>Nucleic Acids Research</i> 26:4910-4916 (1998)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	--------------------------------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>	<b>Serial No.</b>
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		02-742-F (400/132)	10/665,951
		<b>Applicant:</b>  McSwiggen et al.	
		<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>

AB	72.	Allshire, "RNAi and Heterochromatin - A Hushed-up Affair," <i>Science</i> 297:1818-1819 (2002)
	73.	Andrews and Faller, "A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells," <i>Nucleic Acids Research</i> 19:2499 (1991)
	74.	Autiero et al., "Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1," <i>Nature Medicine</i> , 9:936-943 (2003)
	75.	Baenziger and Fiete, "Galactose and N-Acetylgalactosamine-Specific Endocytosis of Glycopeptides by Isolated Rat Hepatocytes," <i>Cell</i> 22:611-620 (1980)
	76.	Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999)
	77.	Bannai et al., "Effect of Injection of Antisense of Oligodeoxynucleotides of GAD Isozymes into Rat Ventromedial Hypothalamus on Food Intake and Locomotor Activity," <i>Brain Research</i> 784:305-315 (1998)
	78.	Bannai et al., "Water-absorbent Polymer as a Carrier for a Discrete Deposit of Antisense Oligodeoxynucleotides in the Central Nervous System," <i>Brain Research Protocols</i> 3:83-87 (1998)
	79.	Bass, "The short answer," <i>Nature</i> 411:428-429 (2001)
	80.	Bass, "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> , 101, 235-238 (2000)
	81.	Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <i>Tetrahedron</i> 49:1925-1963 (1993)
	82.	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <i>The Journal of Biological Chemistry</i> 270:25702-25708 (1995)
	83.	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <i>Nucleosides &amp; Nucleotides</i> 16:951-954 (1997)
✓	84.	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <i>Bioconjugate Chem.</i> 8:204-212 (1997)

<b>EXAMINER</b>  /Amy Bowman/	<b>DATE CONSIDERED</b>  06/08/2006
-------------------------------------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 02-742-F (400/132)	<b>Serial No.</b> 10/665,951
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> September 18, 2003	<b>Group:</b>

AB	85.	Berkman et al., "Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms," The Journal of Clinical Investigation, Inc. 91:153-159 (1993)
	86.	Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," Nature 409:363-366 (2001)
	87.	Bettinger et al., "Size Reduction of Galactosylated PEI/DNA Complexes Improves Lectin-Mediated Gene Transfer into Hepatocytes," <i>Bioconjugate Chem.</i> , 10, 558-561 (1999)
	88.	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," Journal of Pharmaceutical Sciences 87:1308-1315 (1998)
	89.	Boado, "Antisense drug delivery through the blood-brain barrier," Advanced Drug Delivery Reviews 15:73-107 (1995)
	90.	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," Biotechnology and Bioengineering (Combinatorial Chemistry) 61:33-45 (1998)
	91.	Broaddus et al., "Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion," J Neurosurg 88:734-742 (1998)
	92.	Brody and Gold, "Aptamers as therapeutic and diagnostic agents," Reviews in Molecular Biotechnology 74:5-13 (2000)
	93.	Burger et al., "Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation," Cornea 4:35-41 (1985/1986)
	94.	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," Biochemistry 35:14090-14097 (1996) (volume no. mistakenly listed as 6)
	95.	Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," Bioorganic & Medicinal Chemistry 5:1999-2010 (1997)
↓	96.	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," Methods in Enzymology 211:3-19 (1992)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  02-742-F (400/132)	<b>Serial No.</b>  10/665,951
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b>  McSwiggen et al.	
		<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>

AB	97.	Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <i>Nucleic Acids Research</i> 20:4581-4589 (1992)
	98.	Chiu et al., "siRNA function in RNAi: A chemical modification analysis," <i>RNA</i> , 9:1034-1048 (2003)
	99.	Choi et al., "Effect of Poly(ethylene glycol) Grafting on Polyethylenimine as a Gene Transfer Vector <i>in vitro</i> ," <i>Bull. Korean Chem. Soc.</i> , 22, 46-52 (2001)
	100.	Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <i>J. Biol. Chem.</i> 269:25856-25864 (1994)
	101.	Clark and Yoria, "Ophthalmic Drug Discovery," <i>Nature</i> , 2, 448-459 (2003)
	102.	Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function," <i>J. Interferon &amp; Cytokine Res.</i> , 17, 503-524 (1997)
	103.	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <i>J. Am. Chem. Soc.</i> 113:6324-6326 (1991)
	104.	Connolly et al., "Binding and Endocytosis of Cluster Glycosides by Rabbit Hepatocytes," <i>The Journ. of Biol. Chem.</i> 257:939-945 (1982)
	105.	Conry et al., "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration," <i>Clinical Cancer Research</i> 5:2330-2337 (1999)
	106.	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <i>Trends In Genetics</i> 12:510-515 (1996)
	107.	Detmar et al., "Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasis," <i>J. Exp. Med.</i> 180:1141-1146 (1994)
V	108.	Diebold et al., "Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells*," <i>The Journal of Biological Chemistry</i> , 274, 19087-19094 (1999)

<b>EXAMINER</b>  /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
-------------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		<b>Atty. Docket No.</b>  02-742-F (400/132)	<b>Serial No.</b>  10/665,951
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b>  McSwiggen et al.		
		<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>	

AB	109.	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <i>Journal of Virology</i> 66:1432-1441 (1992)
	110.	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <i>Nucleic Acids Research</i> 18:6353-6359 (1990) [sometimes referred to as Seela and Kaiser]
	111.	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <i>Biopolymers</i> 48:39-55 (1998)
	112.	Economides et al., "Cytokine traps: multi-component, high-affinity blockers of cytokine action," <i>Nature Medicine</i> , 9, 1, 47-52 (2003)
	113.	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001)
	114.	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)
	115.	Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <i>Genes and Development</i> 15:188-200 (2001)
	116.	Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <i>Delivery Strategies for Antisense Oligonucleotide Therapeutics</i> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
	117.	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:6743-6747 (1990)
	118.	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <i>Cell Transplantation</i> 8:47-58 (1999)
↓	119.	Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and <i>In Vivo</i> , Using $\beta$ -Cyclodextrin-Adamantane-Oligonucleotide Conjugates," <i>Antisense Nuc. Acid Drug Dev.</i> , 10:469-478 (2000)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>	<b>Serial No.</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		02-742-F (400/132)	10/665,951
		<b>Applicant:</b>  McSwiggen et al.	
		<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>

AB	120.	Erbacher et al., "Transfection and physical properties of various sacccharide, poly(ethylene glycol), and antibody-derivatized polyethylenimines (PEI), <i>The Journal of Gene Medicine</i> , 1, 210-222 (1999) [sometimes incorrectly cited as pages 1-18]
	121.	Fava et al., "Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): Accumulation and Expression in Human Synovial Fluids and Rheumatoid Synovial Tissue," <i>J. Exp. Med.</i> 180:341-346 (1994)
	122.	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <i>J. Am. Chem. Soc.</i> 113:4000-4002 (1991)
	123.	Filleur et al., "SiRNA-mediated Inhibition of Vascular Endothelial Growth Factor Severely Limits Tumor Resistance to Antiangiogenic Thrombospondin-1 and Slows Tumor Vascularization and Growth," <i>Cancer Research</i> , 63, 3919-3922 (2003)
	124.	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998)
	125.	Fire, "RNA-triggered Gene Silencing," <i>TIG</i> 15:358-363(1999)
	126.	Folkman et al., "Long-term Culture of Capillary Endothelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> 76:5217-5221 (1979)
	127.	Folkman, Judah, "Tumor Angiogenesis," <i>Advances in Cancer Research</i> 43:175-203 (1985)
	128.	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <i>Proc. Natl. Acad. Sci. USA</i> 83:9373-9377 (1986) [sometimes referred to as Frier]
	129.	Furgeson et al., "Modified Linear Polyethylenimine—Cholesterol Conjugates for DNA Complexation," <i>Bioconjugate Chem.</i> , 14, 840-847 (2003)
	130.	Futami et al., "Induction fo apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002)
	131.	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <i>Nucleic Acids Research</i> 21:2867-2872 (1993)
V	132.	Genbank Accession No. AF020393

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**FORM PTO-1449**  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-742-F  
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

McSwiggen et al.

**Filing Date:**

September 18, 2003

**Group:**

AB	133.	Genbank Accession No. AF022375
	134.	Genbank Accession No. AF024710
	135.	Genbank Accession No. AF035121
	136.	Genbank Accession No. AF063657
	137.	Genbank Accession No. AF063658
	138.	Genbank Accession No. AF092125
	139.	Genbank Accession No. AF092126
	140.	Genbank Accession No. AF092127
	141.	Genbank Accession No. AF095785
	142.	Genbank Accession No. AF098331
	143.	Genbank Accession No. AF437895
	144.	Genbank Accession No. AF468110
	145.	Genbank Accession No. AF486837
	146.	Genbank Accession No. AH006909
	147.	Genbank Accession No. AJ000185
	148.	Genbank Accession No. AJ010438
	149.	Genbank Accession No. AY047581
✓	150.	Genbank Accession No. D89630
	151.	Genbank Accession No. E13256

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-742-F  
(400/132)

Serial No.

10/665,951

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

September 18, 2003

Group:

AB	152.	Genbank Accession No. E13332
	153.	Genbank Accession No. E14000
	154.	Genbank Accession No. E14233
	155.	Genbank Accession No. E15156
	156.	Genbank Accession No. E15157
	157.	Genbank Accession No. NM_002019
	158.	Genbank Accession No. NM_002020
	159.	Genbank Accession No. NM_002253
	160.	Genbank Accession No. NM_003376
	161.	Genbank Accession No. NM_003377
	162.	Genbank Accession No. NM_004469
	163.	Genbank Accession No. NM_005429
	164.	Genbank Accession No. U01134
	165.	Genbank Accession No. X62568
	166.	Genbank Accession No. X94216
	167.	Genbank Accession No. Y08736
	168.	Godbey et al., "Poly(ethylenimine) and its role in gene delivery," <i>Journal of Controlled Release</i> , 60, 149-160 (1999)
	169.	Godbey et al., "Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery," <i>Proc. Natl. Acad. Sci. USA</i> , 96, 5177-5181 (1999)
	170.	Gold et al., "Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> 64:763-797 (1995)

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 02-742-F (400/132)	<b>Serial No.</b> 10/665,951
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> September 18, 2003	<b>Group:</b>

AB	171.	Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," Bioconjugate Chem. 10:1068-1074 (1999)
	172.	Good et al., "Expression of small, therapeutic RNAs in human nuclei," Gene Therapy 4:45-54 (1997)
	173.	Grant et al., "Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor," Diabetologia 36:282-291 (1993)
	174.	Hall et al., "Establishment and Maintenance of a Heterochromatin Domain," Science 297:2232-2237 (2002)
	175.	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," Science, 286, 950-952 (1999)
	176.	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in Drosophila Cells," Nature 404:293-296 (2000)
	177.	Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," Antisense and Nucleic Acid Drug Development, 13:83-105 (2003)
	178.	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," Science 287:820-825 (2000)
	179.	Hofland and Huang, "Formulation and Delivery of Nucleic Acids," Handbook of Exp. Pharmacol. 137:165-192 (1999)
	180.	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," VCH, 331-417 (1995)
	181.	Hutvagner and Zamore, "A MicroRNA in a Multiple-Turnover RNAi Enzyme Complex," Science 297:2056-2060 (2002)
	182.	Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA," Science 293:834-838 (2001)
▼	183.	International Search Report for PCT/US03/05028 mailed October 17, 2003

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	--------------------------------------

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>	<b>Serial No.</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		02-742-F (400/132)	10/665,951
		<b>Applicant:</b>  McSwiggen et al.	
		<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>

AB	184.	International Search Report for PCT/US03/05346 mailed October 17, 2003
	185.	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," Chem. Pharm. Bull. 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
	186.	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," Science 229:345-352 (1985)
	187.	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic Oligonucleotides," Tetrahedron Letters 34:301-304 (1993) (sometimes mistakenly referred to as Jsckhe)
	188.	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," Clinical Chemistry 45:1628-1650 (1999)
	189.	Jenuwein, "An RNA-Guided Pathway for the Epigenome," Science 297:2215-2218 (2002)
	190.	Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," Fundam. Clin. Pharmacol. 13:16-26 (1999)
	191.	Karle et al., "Differential Changes in Induced Seizures After Hippocampal Treatment of Rats with an Antisense Oligodeoxynucleotide to the GABA <sub>A</sub> Receptor $\gamma 2$ Subunit," Euro. Jour. of Pharmacology 340:153-160 (1997)
	192.	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," Tetrahedron Letters 39:1131-1134 (1998)
	193.	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," Antisense Research & Development 2:3-15 (1992)
	194.	Kaspereit-Rittinghausen et al., "Animal Model of Human Disease: Hereditary Polycystic Kidney Disease," Amer. Journ. of Pathology 139:693-696 (1991)
✓	195.	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature 362:841-844 (1993)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b>  06/08/2006
------------------------------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 02-742-F (400/132)	<b>Serial No.</b> 10/665,951
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>		<b>Applicant:</b> McSwiggen et al.	
(Use several sheets if necessary)		<b>Filing Date:</b> September 18, 2003	<b>Group:</b>

AB	196.	Koch et al., "Vascular Endothelial Growth Factor," Journal of Immunology 152:4149-4156 (1994)
	197.	Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," Reviews in Molecular Biotechnology 74:27-38 (2000)
	198.	Kwak et al., "VEGF Is Major Stimulator in Model of Choroidal Neovascularization," Investigative Ophthalmology & Visual Science, 41(10), 3158-3164 (2000)
	199.	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," Chemical Reviews 95:2601-2627 (1995)
	200.	Lasic and Papahadjopoulos, "Liposomes Revisited," Science 267:1275-1276 (1995)
	201.	Lee and Larson, "Modified Liposome Formulations for Cytosolic Delivery of Macromolecules," ACS Symposium Series 752:184-192 (2000)
	202.	Lee and Lee, "Preparation of Cluster Glycosides of N-Acetylgalactosamine That Have Subnanomolar Binding Constants Towards the Mammalian Hepatic Gal/GalNAc-specific Receptor," Glyconjugates J. 4:317-328 (1987)
	203.	Lee et al., "Expression of Small Interfering RNA's Targeted Against HIV-1 rev Transcripts in Human Cells," Nature Biotechnology 19:500-505 (2002)
	204.	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)
	205.	Lepri et al., "Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization," Journal of Ocular Pharmacology 10:273-281 (1994)
	206.	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in $\alpha$ -Lactalbumin mRNA Levels in C1271 Mouse," EMBO J. 11:4411-4418 (1992)
✓	207.	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods Enzymol. 217:47-66 (1993)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 02-742-F (400/132)	<b>Serial No.</b> 10/665,951
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> September 18, 2003	<b>Group:</b>

AB	208.	Limbach et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2196 (1994)
	209.	Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <i>J. Am. Chem. Soc.</i> 120:8531-8532 (1998)
	210.	Lin et al., "A Novel mRNA-crRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
	211.	Lin et al., "Policing Rogue Genes", <i>Nature</i> 402:128-129 (1999)
	212.	Liszewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:8000-8004 (1993)
	213.	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)
	214.	Loakes, "The Applications of Universal DNA Base Analogues," <i>Nucleic Acids Research</i> 29:2437-2447 (2001)
	215.	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <i>Nucleic Acids Research</i> 21:2585-2589 (1993)
	216.	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <i>Biochemistry</i> 32:1751-1758 (1993)
	217.	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> 110:563-574 (2002)
	218.	Maurer et al., "Lipid-based systems for the intracellular delivery of genetic drugs," <i>Molecular Membrane Biology</i> 16:129-140 (1999)
✓	219.	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <i>Nucleosides &amp; Nucleotides</i> 10:287-290 (1991)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 02-742-F (400/132)	<b>Serial No.</b> 10/665,951
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> September 18, 2003	<b>Group:</b>

AB	220.	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," Proc. Natl. Acad. Sci. USA 83:399-403 (1986)
	221.	McLaren et al., "Vascular Endothelial Growth Factor (VEGF) Concentrations are Elevated in Peritoneal Fluid of Women with Endometriosis," Human Reproduction 11:220-223 (1996)
	222.	McLaren et al., "Vascular Endothelial Growth Factor is Produced by Peritoneal Fluid Macrophages in Endometriosis and Is Regulated by Ovarian Steroids," J. Clin. Invest. 98:482-489 (1996)
	223.	McManus et al., "Gene Silencing Using Micro-RNA Designed Hairpins," RNA 8:842-850 (2002)
	224.	Mesmaeker et al., "Novel Backbone Replacements for Oligonucleotides," American Chemical Society, pp. 24-39 (1994)
	225.	Millauer et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant," Letters to Nature 367:576-579 (1994)
	226.	Miller et al., "Vascular Endothelial Growth Factor/Vascular Permeability Factor is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model," American Journal of Pathology 145:574-584 (1994)
	227.	Miyagishi and Taira, "U6 Promoter-driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells," Nature Biotechnology 19:497-500 (2002)
	228.	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," Science 256:992-996 (1992)
	229.	Mori et al., "Inhibition of Choroidal Neovascularization by Intravenous Injection of Adenoviral Vectors Expressing Secreted Endostatin," American Journal of Pathology, 159(1), 313-320 (2001)
	230.	Mori et al., "Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization," Journal of Cellular Physiology, 118(2) 253-263 (2001)
✓	231.	Noonberg et al., In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," Nucleic Acids Research 22(14):2830-2836 (1994)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  02-742-F (400/132)	<b>Serial No.</b>  10/665,951
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>		<b>Applicant:</b>  McSwiggen et al.	
(Use several sheets if necessary)		<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>

AB	232.	Norby, "Angiogenesis: new aspects relating to its initiation and control," APMIA 105:417-437 (1997)
	233.	Novina et al., "siRNA-Directed Inhibition of HIV-1 Infection," Nature Medicine 1:6 (2002)
	234.	Nykanen et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," Cell 107:309-321 (2001)
	235.	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," Nucleic Acids Symp. Ser. 27:15-16 (1992)
	236.	Ohno-Matsui, et al., "Inducible Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe Proliferative Retinopathy and Retinal Detachment," <i>Animal Models</i> from the Departments of Ophthalmology and Neuroscience and Molecular Biology and Genetics, <i>Am. J. Pathology</i> , 160, 711-719 (2002)
	237.	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," Proc. Natl. Acad. Sci. USA 89:10802-10806 (1992)
	238.	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," Biochimica et Biophysica Acta 1238:86-90 (1995)
	239.	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," Biochemistry 30:9914-9921 (1991)
	240.	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," Cell 79:315-328 (1994)
	241.	Orgis et al., "DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression," <i>AAPS PharmSci.</i> , 3 (3) article 21 ( <a href="http://www.pharmsci.org">http://www.pharmsci.org</a> ) p. 1- 11 (2001)
	242.	Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," American Journal of Pathology 137:1243-1252 (1990)
↓	243.	Pal-Bhadra et al., "Heterochromatic Silencing and HP1 Localization in <i>Drosophila</i> Are Dependent on the RNAi Machinery," <i>Science</i> , 303, 669-672 (2004)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  02-742-F (400/132)	<b>Serial No.</b>  10/665,951
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b>  McSwiggen et al.	
		<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>

AB	244.	Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- $\alpha$ -Induced Angiogenesis," Science 268:567-569 (1995)
	245.	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo," Proc. Natl. Acad. Sci. USA 92:5592-5596 (1995)
	246.	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," Molecular Cell 6:1077-1087 (2000)
	247.	Passaniti et al., "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," Laboratory Investigation 67:519-528 (1992)
	248.	Paul et al., "Effective Expression of Small Interfering RNA in Human Cells," Nature Biotechnology 20:505-508 (2002)
	249.	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," Nature 344:565-567 (1990) (often mistakenly listed as Perrault)
	250.	Petersen et al., "Polyethylenimine-graft-Poly(ethylene glycol) Copolymers: Influence of Copolymer Block Structure on DNA Complexation and Biological Activities as Gene Delivery System," <i>Bioconjugate Chem.</i> , 13, 845-854 (2002)
	251.	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," Science 253:314-317 (1991)
	252.	Pierce et al., "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," Proc. Natl. Acad. Sci. USA 92:905-909 (1995)
	253.	Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas in vivo," Nature 359:845-848 (1992)
	254.	Ponpipom et al., "Cell-Specific Ligands for Selective Drug Delivery to Tissues and Organs," J. Med. Chem. 24:1388-1395 (1981)
✓	255.	Rajakumar et al., "Effects of Intrastriatal Infusion of D <sub>2</sub> Receptor Antisense Oligonucleotide on Apomorphine-Induced Behaviors in the Rat," <i>Synapse</i> 26:199-208 (1997)

<b>EXAMINER</b>  /Amy Bowman/	<b>DATE CONSIDERED</b>  06/08/2006
-------------------------------------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 02-742-F (400/132)	<b>Serial No.</b> 10/665,951
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> September 18, 2003	<b>Group:</b>

AB	256.	Reich et al., "Small Interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , 9, 210-216 (2003)
	257.	Reinhart and Bartel, "Small RNAs Correspond to Centromer Heterochromatic Repeats," <i>Science</i> 297:1831 (2002)
	258.	Reinhart et al., "MicroRNAs in Plants," <i>Genes &amp; Development</i> 16:1616-1626 (2002)
	259.	Reynolds et al., "Rational siRNA design for RNA interference," <i>Nature Biotechnology</i> , 22, 3, 326-330 (2004)
	260.	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <i>J. Am. Chem. Soc.</i> 113:5109-5111 (1991)
	261.	Saenger (ed), "Modified Nucleosides and Nucleotides; Nucleoside Di- and Triphosphates; Coenzymes and Antibiotics, (ch.7)" <i>Principles of Nucleic Acid Structure</i> 158-200 (1984)
	262.	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <i>Science</i> 247:1222-1225 (1990)
	263.	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <i>Proc. Natl. Acad. Sci. USA</i> 88:10591-10595 (1991)
	264.	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using $\beta$ -cyanoethyl protected ribonucleoside phosphoramidites," <i>Nucl Acids Res.</i> 18:5433-5441 (1990)
	265.	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <i>Prog. Neuro-Psychopharmacol. &amp; Biol. Psychiat.</i> 23:941-949 (1999) [sometimes cited by RPI as Prog Neuropsychopharmacol Biol Psychiatry 23:941-949, 1999]
	266.	Schwarz et al., "Evidence that siRNAs Function as Guides, Not Primers, in the Drosophila and Human RNAi Pathways," <i>Molecular Cell</i> 10:537-548 (2002)
	267.	Schwarz et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," <i>Cell</i> , 1115, 199-208 (2003)
↓	268.	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <i>Nucleic Acids Research</i> 15:3113-3129 (1987)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.




<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 02-742-F (400/132)	<b>Serial No.</b> 10/665,951
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> September 18, 2003	<b>Group:</b>

AB	269.	Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," <i>Cancer and Metastasis Reviews</i> 12:303-324 (1993)
	270.	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <i>Nucleic Acids Research</i> 19:4247-4251 (1991)
	271.	Sharp, Philip A., "RNAi and Double-strand RNA", <i>Genes and Development</i> 13:139-141 (1999)
	272.	Sheehan et al., "Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides," <i>Nucleic Acids Research</i> , 31 (14), 4109-4118 (2003)
	273.	Shifren et al., "Ovarian Steroid Regulation of Vascular Endothelial Growth Factor in the Human Endometrium: Implications for Angiogenesis during the Menstrual Cycle and in the Pathogenesis of Endometriosis," <i>The Journal of Clinical Endocrinology &amp; Metabolism</i> 81:3112-3118 (1996)
	274.	Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," <i>J. Clin. Invest.</i> 91:2235-2243 (1993)
	275.	Simantov et al., "Dopamine-Induced Apoptosis in Human Neuronal Cells: Inhibition by Nucleic Acids Antisense to the Dopamine Transporter," <i>Neuroscience</i> 74(1):39-50 (1996)
	276.	Sommer et al., "The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain," <i>Antisense &amp; Nucleic Acid Drug Development</i> 8:75-85 (1998)
	277.	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found" <i>Molecular Biology</i> , 286: 5441, p.886 (1999)
	278.	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <i>Science</i> 262:1566-1569 (1993)
↓	279.	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc," <i>Current Opinion in Molecular Therapeutics</i> 2:100-105 (2000)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  02-742-F (400/132)	<b>Serial No.</b>  10/665,951
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>		<b>Applicant:</b>  McSwiggen et al.	
(Use several sheets if necessary)		<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>

AB	280.	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences transcription vectors," <i>Nucleic Acids Research</i> 19:5125-5130 (1991)
	281.	Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," <i>Cancer Research</i> 54:4233-4237 (1994)
	282.	Thomas et al., "Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells," <i>PNAS</i> , 99, 14640-14645 (2002)
	283.	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <i>Nucleic Acids Research</i> 23:2259-2268 (1995)
	284.	Turner et al., "Improved Parameters for Prediction of RNA Structure," <i>Cold Spring Harbor Symposia on Quantitative Biology Volume LII</i> , pp. 123-133 (1987)
	285.	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <i>J. Am. Chem. Soc.</i> 109:3783-3785 (1987)
	286.	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <i>Genes &amp; Development</i> 13:3191-3197 (1999)
	287.	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002)
	288.	Tuschl, "RNA Interference and Small Interfering RNAs," <i>Chembiochem</i> 2:239-245 (2001)
	289.	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci. USA</i> 96:7053-7058 (1999)
	290.	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <i>FEBS Letters</i> 421:280-284 (1998)

<b>EXAMINER</b>  /Amy Bowman/	<b>DATE CONSIDERED</b>  06/08/2006
-------------------------------------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>	<b>Serial No.</b>
<b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		02-742-F (400/132)	10/665,951
		<b>Applicant:</b>  McSwiggen et al.	
		<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>

AB	291.	Uhlmann et al., "Studies on the Mechanism of Stabilization of Partially Phosphorothioated Oligonucleotides Against Nucleolytic Degradation," <u>Antisense &amp; Nucleic Acid Drug Development</u> 7:345-350 (1997)
	292.	Ui-Tei et al., "Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference," <u>Nucleic Acids Research</u> , 32, 3, 936-948 (2004)
	293.	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <u>TIBS</u> 17:334-339 (1992)
	294.	Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," <u>Annual Reports in Medicinal Chemistry</u> 30:285-294 (1995)
	295.	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an Escherichia coli Formylmethionine tRNA," <u>J. Am. Chem. Soc.</u> 109:7845-7854 (1987)
	296.	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <u>Nucleic Acids Symposium Series</u> 31:163-164 (1994)
	297.	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <u>Nucleic Acids Research</u> 21:3249-3255 (1993)
	298.	Verdel et al., "RNAi-Mediated Targeting of Heterochromatin by the RITS Complex," <u>Science</u> , 303, 672-676 (2004)
	299.	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <u>Annu. Rev. Biochem.</u> 67:99-134 (1998)
	300.	Volpe et al., "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi," <u>Science</u> 297:1833-1837 (2002)
	301.	Waterhouse, et al. "Virus Resistance and gene Silencing in Plants Can Be Induced by Simultaneous Expression of Sense and Antisense RNA" <u>Proc. Natl. Acad. Sci. USA</u> 99:13959-13964 (1998)
✓	302.	Weckbecker et al., "Intradermal angiogenesis in nude mice induced by human tumor cells or b-FGF," <u>Angiogenesis Key Principles—Science—Technology—Medicine</u> pp296-301 (1992)

<b>EXAMINER</b>  /Amy Bowman/	<b>DATE CONSIDERED</b>  06/08/2006
-------------------------------------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 02-742-F (400/132)	<b>Serial No.</b> 10/665,951
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> September 18, 2003	<b>Group:</b>

AB	303.	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4+ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," Journal of Virology 65:5531-5534 (1994)
	304.	Wellstein and Czubayko, "Inhibition of Fibroblast Growth Factors," Breast Cancer Research and Treatment 38:109-119 (1996)
	305.	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," Nature Cell Biology 2:70-75 (2000)
	306.	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," Nucleic Acids Research 23(14):2677-2684 (1995)
	307.	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," Methods in Molecular Biology 74:59-69 (1997)
	308.	Woo et al., "Taxol Inhibits Progression of Congenital Polycystic Kindey Disease," Nature 368:750-753 (1994)
	309.	Wu and Wu, "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System," The Journ. of Biol. Chem. 262:4429-4432 (1987)
	310.	Wu et al., "Cardiac Defects and Renal Failure in Mice with Targeted Mutations in Pkd2," Nature Genetics 24:75-78 (2000)
	311.	Wu-Pong et al., "Nucleic Acid Drug Delivery, Part 2; Delivery to the Brain," 32-38 (1999)
	312.	Yamada et al., "Nanoparticles for the delivery of genes and drugs to human hepatocytes," Published online: 29 June 2003, doi:10.1038/nbt843 (August 2003 Volume 21 Number 8 pp 885-890) (2003)
	313.	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993)
✓	314.	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," Cell 101:25-33 (2000)

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
---------------------------------	--------------------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No.	Serial No.		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	02-742-F (400/132)		10/665,951			
	Applicant:					
	McSwiggen et al.					
Filing Date:		Group:				
September 18, 2003						

AB	315.	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," Mol. Cell. Biol. 10:4529-4537 (1990)
AB	316.	Ziche et al., "Angiogenesis Can Be Stimulated or Repressed In Vivo by a Change in GM3:GD3 Ganglioside Ratio," Laboratory Investigation 67:711-715 (1992)

EXAMINER  /Amy Bowman/	DATE CONSIDERED  06/08/2006
------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	 <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  02-742-F (400/131)	<b>Serial No.</b>  10/665,951
<b>SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b>  McSwiggen et al.	
		<b>Filing Date:</b>  September 18, 2003	<b>Group:</b>

## U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
AB	*	US 2003/0190635	10/2003	McSwiggen et al.			
AB	*	US 2003/0206887	11/2003	Morrissey et al.			

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
AB	*	6,346,398	02/12/02	Pavco et al.			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
AB	*	1325955	07/09/03	EP (Klippel-Giese et al.)				
AB	*	08208687	08/1996	JP (Hotoda et al.)				

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b> 06/08/2006
------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-742-F  
(400/131)

Serial No.

10/665,951

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

McSwiggen et al.

**Filing Date:**

September 18, 2003

**Group:**

AB	*	94/11499	05/26/94	WO (Ullrich et al.)				
	*	94/21791	09/29/94	WO (Bergmann et al.)				
	*	95/04142	02/09/95	WO (Robinson)				
	*	95/13380	05/18/95	WO (Draper et al.)				
	*	97/00957	01/09/97	WO (Patterson-Winston et al.)				
	*	97/21808	06/19/97	WO (Robinson)				
	*	99/04819	02/04/99	WO (Klimuk et al.)				
	*	99/55857	11/04/99	Wo (Beigelman et al.)				
	*	00/21560	04/20/00	WO (Alitalo et al.)				
	*	01/097850	12/27/01	WO (Siemeister et al.)				
	*	02/07747	01/31/02	WO (King)				
	*	02/10378	02/07/02	WO (Cowser et al.)				
	*	02/096927	12/05/02	WO (Escobedo et al.)				
	*	03/068797	08/21/03	WO (Rossi et al.)				
	*	03/070887	08/28/03	WO (McSwiggen et al.)				
	*	03/070896	08/28/03	WO (McSwiggen et al.)				
	*	03/070910	08/28/03	WO (McSwiggen et al.)				
	*	03/074654	09/12/03	WO (McSwiggen et al.)				
	*	03/080638	10/02/03	WO (Lacasse et al.)				

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>	<b>Serial No.</b>
<b>SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>		02-742-F (400/131)	10/665,951
(Use several sheets if necessary)		<b>Applicant:</b>	
		McSwiggen et al.	
		<b>Filing Date:</b>	<b>Group:</b>
		September 18, 2003	

AB	*	04/009769	01/29/04	WO (Tolentino et al.)				
↓	*	04/043977	05/27/04	WO (Prakush et al.)				
↓	*	04/072261	08/26/04	WO (Li et al.)				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

AB	*	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," <i>Oligonucleotides</i> , 13:303-312 (2003)
↓	*	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglycerol derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
↓	*	Hasan et al., "VEGF antagonists," <i>Oncologic, Metabolic &amp; Endocrine</i> , 703-718 (2001)
↓	*	International Search Report for PCT/US03/05022 mailed January 6, 2005
↓	*	International Search Report for PCT/US2004/016390 mailed March 31, 2005
↓	*	International Search Report for PCT/US2004/027403 mailed July 12, 2005
↓	*	International Search Report for PCT/US2004/030488 mailed January 12, 2005
↓	*	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)
↓	*	Kuwabara et al., "A C. elegans patched gene, ptc-1, functions in germ-line cytokinesis," <i>Genes and Development</i> , 14(15):1933-1944 (2000)
↓	*	Lu et al., "Tumor Inhibition By RNAi-Mediated VEGF an VEGFR2 Down Regulation in Xenograft Models," <i>Cancer Gene Therapy</i> , 10, Suppl. 1, S4-S5 (2003)
↓	*	Parry et al. 1999. "Bioactivity of anti-angiogenic ribozymes targeting <i>Flt-1</i> and <i>KDR</i> mRNA," <i>Nucleic Acid Res.</i> 27:2569-77

<b>EXAMINER</b> /Amy Bowman/	<b>DATE CONSIDERED</b>
	06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

02-742-F  
(400/131)

Serial No.

10/665,951

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

McSwiggen et al.

**Filing Date:**

September 18, 2003

**Group:**

AB

\*

Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (*flt*) closely related to the *fms* family," *Oncogene* 5:519-524 (1990)

EXAMINER

/Amy Bowman/

DATE CONSIDERED

06/08/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.